Compounds > 3-cyano-2-morpholino-5-(pyrid-4-yl)pyridine
Page last updated: 2024-12-07

3-cyano-2-morpholino-5-(pyrid-4-yl)pyridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID130952
SCHEMBL ID3362140
MeSH IDM0207989

Synonyms (10)

Synonym
2-morpholin-4-yl-5-pyridin-4-ylpyridine-3-carbonitrile
108610-78-2
(3,4'-bipyridine)-5-carbonitrile, 6-(4-morpholinyl)-
awd-122-14
awd 122-14
3-cyano-2-morpholino-5-(pyrid-4-yl)pyridine
SCHEMBL3362140
WNXSIPLQLUDQDP-UHFFFAOYSA-N
3-cyano-2-morpholino-5-(pyrid-4-yl)-pyridine
DTXSID90148607

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic parameters were estimated."( [Pharmacokinetics and biotransformation of 3-cyan-2-morpholino-5-(pyrid-4-yl)pyridine (AWD 122-14) in the rat].
Böhme, B; Franke, P; Hagen, V; Kunter, U; Labes, D; Vagaday, M, 1994)		0.29

Bioavailability

ExcerptReferenceRelevance
" The absolute bioavailability of a single oral dose equals 11%."( [Pharmacokinetics and biotransformation of 3-cyan-2-morpholino-5-(pyrid-4-yl)pyridine (AWD 122-14) in the rat].
Böhme, B; Franke, P; Hagen, V; Kunter, U; Labes, D; Vagaday, M, 1994)		0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.50 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
amrinone
Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.. amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.		1.9810bipyridinesEC 3.1.4.* (phosphoric diester hydrolase) inhibitor
milrinone
[no description available]		2.3820bipyridines;
nitrile;
pyridone		cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
ConditionIndicatedRelationship StrengthStudiesTrials
Anesthesia
A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.		01.9810
Injury, Myocardial Reperfusion
[description not available]		01.9810